Tilray vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tilray Inc (TLRY)

Q3 202615 Jul – 9 Oct 2026

▲2▼1

Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble

BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.
A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.
Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.
This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.
Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.
Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.
Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.
This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.

August 202615 Jul – 9 Oct 2026

▲2▼1

Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble

BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.
A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.
Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.
This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.
Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.
Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.
Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.
This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.

Latest15 Jul – 9 Oct 2026

▲2▼1

Tilray's Beverage Bet Grows as Cannabis and Rescheduling Stumble

BrewDog founder bids to buy back UK business James Watt, BrewDog's founder, has formally offered to buy back the UK business from Tilray through his new venture, with 43,000 investors backing him. If successful, Tilray would lose a key asset, shrinking its beverage alcohol base and potentially its future earnings power.
A credible bid for a major Tilray asset could reduce the company's value and is a real negative force.
Record revenue and sharply lower net loss Tilray reported record fiscal 2026 net revenue of $915.5 million, up 11%, while its annual net loss narrowed to $105.2 million from nearly $2.2 billion. That huge improvement in profitability, plus net debt cut to just $700,000, strengthens the balance sheet and supports the stock.
This is the core fundamental improvement that makes Tilray more financially stable and attractive to investors.
Court lets marijuana rescheduling proceed A federal appeals court rejected a request to temporarily block the Trump administration's move to reclassify marijuana to Schedule III. That keeps the process alive, and Tilray sees it as a chance to eventually expand its medical cannabis business into the U.S., a big potential new market.
Rescheduling progress is a major regulatory catalyst that could open the U.S. market to Tilray.
Beverage alcohol surges but cannabis slumps; DEA pauses hearing In its fiscal first quarter, Tilray's beverage alcohol revenue jumped 82.6% while cannabis revenue fell 11.8%. The DEA also paused a cannabis rescheduling hearing, a regulatory setback. The company reaffirmed its fiscal 2027 outlook, but the mixed results and wider-than-expected loss sent shares down 3.4%.
This shows the tug-of-war: strong beverage growth versus weak cannabis and a rescheduling delay, which together drive the stock's recent weakness.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.